CHEMBIO DIAGNOSTIC SYSTEMS, INC.

Chembio Diagnostics, Inc. is a leading developer and manufacturer of rapid point-of-care (POC) diagnostic tests for infectious diseases, headquartered in Hauppauge, New York, with operations in Medford, New York. The company specializes in innovative diagnostic solutions utilizing its proprietary Dual Path Platform (DPP®) technology, which delivers improved sensitivity, multiplexing capabilities, and rapid results from a small sample of fingertip blood. Chembio's product portfolio includes FDA-approved and CLIA-waived assays for HIV, syphilis, Hepatitis C, COVID-19, and emerging infectious disease detection. The company also develops quantitative diagnostics (FastPack® hCG) and is actively advancing diagnostics for typhoid fever and preeclampsia. With 337 employees and approximately $55.3 million in annual revenue, Chembio markets its solutions to medical laboratories, hospitals, government health agencies, NGOs, and retail establishments across the United States and internationally. The company is committed to delivering exceptional, easy-to-use, fast, and accurate diagnostic solutions to enhance health outcomes in infectious disease detection and monitoring.